ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Panel Debates Whether DCIS Needs A New Name

September 25, 2009

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

New Drug Combination Shrinks Kidney Cancers

June 30, 2006

How ImClone’s “Hot” New Drug Got Cold Shoulder From FDA

March 8, 2002

Abstracts Of “Most Newsworthy” Papers At AACR Meeting

May 27, 1977

ACS Offers New Grants to Physicians

September 7, 1984